Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy (Q36428713)

14 August 2017

1 reference

title

Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy (English)

1 reference

14 August 2017

0 references

0 references

1 reference

Gene D Morse

1

1 reference

PubMed ID

16554246

14 August 2017

Linda M Catanzaro

series ordinal

2

1 reference

PubMed ID

16554246

14 August 2017

Edward P Acosta

series ordinal

3

1 reference

14 August 2017

1 April 2006

1 reference

Lancet Infectious Diseases

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

215-225

1 reference

14 August 2017

4

1 reference

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Latent reservoirs of HIV: obstacles to the eradication of virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

The human immunodeficiency virus: infectivity and mechanisms of pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

The reaction between acetyl choline and muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

HIV-1 dynamics in vivo: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Genotypic-resistance assays and antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapte

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Tipranavir: a ritonavir-boosted protease inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Predictors of virological response to atazanavir in protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970436-4

7 January 2021

10.1016/S1473-3099(06)70436-4

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16554246